Patents by Inventor Milan Fiala

Milan Fiala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for diagnosing alzheimer's disease
    Patent number: 7771957
    Abstract: The invention relates to method of diagnosing Alzheimer's disease or detecting a predisposition to Alzheimer's disease including providing a test cell sample from a subject, exposing the test cell sample to labeled amyloid beta peptides, and determining the level of labeled amyloid beta peptides in the test cell sample, wherein lower levels of labeled amyloid beta peptides in the test cell sample compared to a control cell sample are indicative of Alzheimer's disease.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: August 10, 2010
    Assignee: The Regents of the University of California
    Inventor: Milan Fiala
  • Diagnostic Methods and Genetic Markers for Alzheimer Disease
    Publication number: 20090263492
    Abstract: Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for use in animal models of neurodegenerative diseases.
    Type: Application
    Filed: March 19, 2009
    Publication date: October 22, 2009
    Inventors: John R. Cashman, Milan Fiala
  • USE OF BIOMARKERS OF ALZHEIMER'S DISEASE FOR DIAGNOSTIC TESTS AND DRUG SCREENING
    Publication number: 20090104629
    Abstract: The invention relates to method of diagnosing Alzheimer's disease or detecting a predisposition to Alzheimer's disease including providing a test cell sample from a subject, exposing the test cell sample to labeled amyloid beta peptides, and determining the level of labeled amyloid beta peptides in the test cell sample, wherein lower levels of labeled amyloid beta peptides in the test cell sample compared to a control cell sample are indicative of Alzheimer's disease.
    Type: Application
    Filed: October 19, 2007
    Publication date: April 23, 2009
    Applicant: MP Biomedicals LLC
    Inventor: Milan Fiala